Pergolide for levodopa-induced complications in Parkinson’s disease
Abstract Background In later Parkinson’s disease, long-term treatment with levodopa therapy is associated with the development of motor complications which include abnormal involuntary movements (dyskinesia) and a shortening response to each dose (wearing off phenomenon). Dopamine agonists have been used in such patients in the hope that they can reduce the duration of immobile off […]
Lisuride for levodopa-induced complications in Parkinson’s disease
Abstract Background Long-term levodopa therapy in Parkinson’s disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor […]
Lisuride versus bromocriptine for levodopa-induced complications in Parkinson’s disease
Abstract Background Long-term levodopa therapy in Parkinson’s disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor […]
Bromocriptine for levodopa-induced motor complications in Parkinson’s disease
Abstract Background Motor Complications are an important issue in the management of patients with Parkinson’s disease and dopamine agonists have been introduced to ameliorate this problem. Objectives To assess the efficacy and safety of adjunct bromocriptine (BR) therapy compared to placebo in the treatment of Parkinson’s disease (PD) patients with motor complications. Search methods Sources […]